Horizon Therapeutics announced the Brazilian Health Regulatory Agency, or ANVISA, has approved Uplizna as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+. This rare autoimmune disease is caused by inflammation in the central nervous system, resulting in severe and recurrent attacks that can lead to permanent disability, such as paralysis and vision loss.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HZNP:
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Viridian Therapeutics initiated with a Buy at Needham
- Horizon Pharma call volume above normal and directionally bullish
- John Paulson Hits the Jackpot With Horizon Buyout — Here Are His 2 Top Stocks Right Now
- Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital